Melanie Daniel, MD, Lille Hospital University, Lille, France, comments on current challenges in the treatment of von Willebrand disease (VWD), particularly type 2N. Dr Daniel highlights that some patients have normal levels of the VW factor (VWF), which means VWF replacement therapy may be problematic, and suggests that new therapeutic approaches being explored in hemophilia could be implemented in VWD. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.